<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00754130</url>
  </required_header>
  <id_info>
    <org_study_id>0941-011</org_study_id>
    <secondary_id>2008_023</secondary_id>
    <secondary_id>MK-0941-011</secondary_id>
    <nct_id>NCT00754130</nct_id>
  </id_info>
  <brief_title>MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011).</brief_title>
  <official_title>A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The multiple dose study to assess the safety, tolerability, pharmacokinetics and
      pharmacodynamics of MK-0941 in Japanese patients with Type 2 Diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Experienced at Least One Adverse Event (AE)</measure>
    <time_frame>Up to 14 days after last dose of study drug</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due to an AE</measure>
    <time_frame>Up to 14 days after last dose of study drug</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Area Under the Concentration-time Curve (AUC)(0-24hr) of MK-0941</measure>
    <time_frame>Up to 72 hours after study drug administration</time_frame>
    <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Maximum Concentration (Cmax) of MK-0941</measure>
    <time_frame>Up to 72 hours after study drug administration</time_frame>
    <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Time to Reach Cmax (Tmax) of MK-0941</measure>
    <time_frame>Up to 72 hours after study drug administration</time_frame>
    <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Concentration of MK-0941 at 24 Hours (C24hr)</measure>
    <time_frame>Up to 72 hours after study drug administration</time_frame>
    <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Apparent Terminal Elimination Half-life (t1/2) of MK-0941</measure>
    <time_frame>Up to 72 hours after study drug administration</time_frame>
    <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr</measure>
    <time_frame>Day 5 and Day 1</time_frame>
    <description>Geometric Mean of the Day 5 to Day 1 Accumulation Ratio</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus, Non-Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Placebo/MK-0941 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 5mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 5mg/MK-0941 20mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/MK-0941 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 10mg/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MK-0941 10mg/MK-0941 40mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2. There was a washout period of at least 8 days between the two treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets before every meal (q.a.c) Treatment period is 5 days.</description>
    <arm_group_label>Placebo/MK-0941 20mg</arm_group_label>
    <arm_group_label>MK-0941 5mg/Placebo</arm_group_label>
    <arm_group_label>Placebo/MK-0941 40mg</arm_group_label>
    <arm_group_label>MK-0941 10mg/Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-0941</intervention_name>
    <description>MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.</description>
    <arm_group_label>Placebo/MK-0941 20mg</arm_group_label>
    <arm_group_label>MK-0941 5mg/Placebo</arm_group_label>
    <arm_group_label>MK-0941 5mg/MK-0941 20mg</arm_group_label>
    <arm_group_label>Placebo/MK-0941 40mg</arm_group_label>
    <arm_group_label>MK-0941 10mg/Placebo</arm_group_label>
    <arm_group_label>MK-0941 10mg/MK-0941 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese Male or Female between 20 to 65 years of age

          -  Diagnosis of Type 2 Diabetes

          -  Patient being treated by diet and exercise alone

        Exclusion Criteria:

          -  Patient has a history of Type 1 Diabetes

          -  Patient is being treated with glaucoma medications

          -  Patient has donated blood or participated in another clinical study in the past 12
             weeks

          -  Patient is a regular user of any illicit drugs or has a history of drug, including
             alcohol, abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2008</study_first_submitted>
  <study_first_submitted_qc>September 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2008</study_first_posted>
  <results_first_submitted>August 31, 2012</results_first_submitted>
  <results_first_submitted_qc>August 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2012</results_first_posted>
  <last_update_submitted>February 23, 2015</last_update_submitted>
  <last_update_submitted_qc>February 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo/MK-0941 20mg</title>
          <description>Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2</description>
        </group>
        <group group_id="P2">
          <title>MK-0941 5mg/Placebo</title>
          <description>Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2</description>
        </group>
        <group group_id="P3">
          <title>MK-0941 5mg/MK-0941 20mg</title>
          <description>Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2</description>
        </group>
        <group group_id="P4">
          <title>Placebo/MK-0941 40mg</title>
          <description>Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2</description>
        </group>
        <group group_id="P5">
          <title>MK-0941 10mg/Placebo</title>
          <description>Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2</description>
        </group>
        <group group_id="P6">
          <title>MK-0941 10mg/MK-0941 40mg</title>
          <description>Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4">One participant received MK-0941 10 mg in both Periods 1 and 2.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (&gt;=8 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2">One participant received MK-0941 15 mg starting with Dose 2 on Day 2.</participants>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4">One participant received MK-0941 35 mg starting with Dose 3 on Day 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/MK-0941 20mg</title>
          <description>Participants received Placebo during Period 1 and MK-0941 20 mg during Period 2</description>
        </group>
        <group group_id="B2">
          <title>MK-0941 5mg/Placebo</title>
          <description>Participants received MK-0941 5 mg during Period 1 and Placebo during Period 2</description>
        </group>
        <group group_id="B3">
          <title>MK-0941 5mg/MK-0941 20mg</title>
          <description>Participants received MK-0941 5 mg during Period 1 and MK-0941 20 mg during Period 2</description>
        </group>
        <group group_id="B4">
          <title>Placebo/MK-0941 40mg</title>
          <description>Participants received Placebo during Period 1 and MK-0941 40 mg during Period 2</description>
        </group>
        <group group_id="B5">
          <title>MK-0941 10mg/Placebo</title>
          <description>Participants received MK-0941 10 mg during Period 1 and Placebo during Period 2</description>
        </group>
        <group group_id="B6">
          <title>MK-0941 10mg/MK-0941 40mg</title>
          <description>Participants received MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="2"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.0" spread="12.73"/>
                    <measurement group_id="B2" value="48.5" spread="2.12"/>
                    <measurement group_id="B3" value="45.5" spread="16.58"/>
                    <measurement group_id="B4" value="57.0" spread="7.07"/>
                    <measurement group_id="B5" value="53.5" spread="10.60"/>
                    <measurement group_id="B6" value="51.5" spread="11.36"/>
                    <measurement group_id="B7" value="50.4" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced at Least One Adverse Event (AE)</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
        <time_frame>Up to 14 days after last dose of study drug</time_frame>
        <population>Safety Population, consisting of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants receiving Placebo doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O5">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily. One participant randomized to receive MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2 received MK-0941 10 mg during both Periods 1 and 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Adverse Event (AE)</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
          <population>Safety Population, consisting of all randomized participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Area Under the Concentration-time Curve (AUC)(0-24hr) of MK-0941</title>
        <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
        <time_frame>Up to 72 hours after study drug administration</time_frame>
        <population>Participants with an AUC(0-24hr) measurement</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Area Under the Concentration-time Curve (AUC)(0-24hr) of MK-0941</title>
          <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
          <population>Participants with an AUC(0-24hr) measurement</population>
          <units>nmol*hr/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="754" spread="165"/>
                    <measurement group_id="O2" value="1900" spread="885"/>
                    <measurement group_id="O3" value="3230" spread="654"/>
                    <measurement group_id="O4" value="8700" spread="2190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="883" spread="157"/>
                    <measurement group_id="O2" value="2360" spread="1260"/>
                    <measurement group_id="O3" value="3560" spread="863"/>
                    <measurement group_id="O4" value="9730" spread="3140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Maximum Concentration (Cmax) of MK-0941</title>
        <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
        <time_frame>Up to 72 hours after study drug administration</time_frame>
        <population>Participants with a Cmax measurement</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Maximum Concentration (Cmax) of MK-0941</title>
          <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
          <population>Participants with a Cmax measurement</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105" spread="21.5"/>
                    <measurement group_id="O2" value="255" spread="116"/>
                    <measurement group_id="O3" value="487" spread="58.3"/>
                    <measurement group_id="O4" value="1340" spread="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" spread="26.2"/>
                    <measurement group_id="O2" value="292" spread="108"/>
                    <measurement group_id="O3" value="509" spread="140"/>
                    <measurement group_id="O4" value="1240" spread="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Time to Reach Cmax (Tmax) of MK-0941</title>
        <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
        <time_frame>Up to 72 hours after study drug administration</time_frame>
        <population>Participants with a Tmax measurement</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Time to Reach Cmax (Tmax) of MK-0941</title>
          <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
          <population>Participants with a Tmax measurement</population>
          <units>hr</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="1.0" upper_limit="11.0"/>
                    <measurement group_id="O2" value="6.0" lower_limit="1.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O4" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="11.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="6.0" lower_limit="6.0" upper_limit="11.0"/>
                    <measurement group_id="O4" value="6.0" lower_limit="6.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Concentration of MK-0941 at 24 Hours (C24hr)</title>
        <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
        <time_frame>Up to 72 hours after study drug administration</time_frame>
        <population>Participants with a C24hr measurement</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Concentration of MK-0941 at 24 Hours (C24hr)</title>
          <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
          <population>Participants with a C24hr measurement</population>
          <units>nmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" spread="3.7"/>
                    <measurement group_id="O2" value="14.6" spread="3.7"/>
                    <measurement group_id="O3" value="27.9" spread="12.8"/>
                    <measurement group_id="O4" value="66.4" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="2.1"/>
                    <measurement group_id="O2" value="26.0" spread="7.4"/>
                    <measurement group_id="O3" value="38.5" spread="12.5"/>
                    <measurement group_id="O4" value="112.8" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Apparent Terminal Elimination Half-life (t1/2) of MK-0941</title>
        <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
        <time_frame>Up to 72 hours after study drug administration</time_frame>
        <population>Participants with a t1/2 measurement</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Apparent Terminal Elimination Half-life (t1/2) of MK-0941</title>
          <description>Blood samples for measurement of plasma pharmacokinetic parameters were collected from predose to up to 24 hours postdose on Day 1 and from predose to up to 72 hours postdose on Day 5 in each treatment period.</description>
          <population>Participants with a t1/2 measurement</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.5"/>
                    <measurement group_id="O2" value="4.4" spread="1.2"/>
                    <measurement group_id="O3" value="4.3" spread="1.1"/>
                    <measurement group_id="O4" value="3.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="2.0"/>
                    <measurement group_id="O2" value="8.3" spread="4.1"/>
                    <measurement group_id="O3" value="9.9" spread="7.2"/>
                    <measurement group_id="O4" value="9.1" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
        <time_frame>Up to 14 days after last dose of study drug</time_frame>
        <population>Safety Population, consisting of all randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants receiving Placebo doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O5">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily. One participant randomized to receive MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2 received MK-0941 10 mg during both Periods 1 and 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due to an AE</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product.
Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</description>
          <population>Safety Population, consisting of all randomized participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr</title>
        <description>Geometric Mean of the Day 5 to Day 1 Accumulation Ratio</description>
        <time_frame>Day 5 and Day 1</time_frame>
        <population>All participants with pharmacokinetic measurements on Days 1 and 5</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0941 5mg</title>
            <description>Participants receiving MK-0941 5 mg doses three times daily</description>
          </group>
          <group group_id="O2">
            <title>MK-0941 10mg</title>
            <description>Participants receiving MK-0941 10 mg doses three times daily</description>
          </group>
          <group group_id="O3">
            <title>MK-0941 20mg</title>
            <description>Participants receiving MK-0941 20 mg doses three times daily</description>
          </group>
          <group group_id="O4">
            <title>MK-0941 40mg</title>
            <description>Participants receiving MK-0941 40 mg doses three times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Pharmacokinetic Parameter: Day 5 to Day 1 Accumulation Ratio for AUC (0-24hr), Cmax, and C24hr</title>
          <description>Geometric Mean of the Day 5 to Day 1 Accumulation Ratio</description>
          <population>All participants with pharmacokinetic measurements on Days 1 and 5</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-24hr) Day 5/Day 1 Accumulation Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.09" upper_limit="1.38"/>
                    <measurement group_id="O2" value="1.28" lower_limit="1.09" upper_limit="1.42"/>
                    <measurement group_id="O3" value="1.09" lower_limit="0.93" upper_limit="1.31"/>
                    <measurement group_id="O4" value="1.1" lower_limit="1.04" upper_limit="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Day 5/Day 1 Accumulation Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" lower_limit="1.05" upper_limit="1.42"/>
                    <measurement group_id="O2" value="1.18" lower_limit="0.87" upper_limit="1.36"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.79" upper_limit="1.28"/>
                    <measurement group_id="O4" value="0.90" lower_limit="0.72" upper_limit="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C24hr Day 5/Day 1 Accumulation Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" lower_limit="0.61" upper_limit="1.96"/>
                    <measurement group_id="O2" value="1.77" lower_limit="1.23" upper_limit="2.19"/>
                    <measurement group_id="O3" value="1.44" lower_limit="0.81" upper_limit="2.01"/>
                    <measurement group_id="O4" value="1.65" lower_limit="1.07" upper_limit="2.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for occurrence AEs for up to 8 days after last dose of study drug during Period 1 and for up to 14 days after last dose of study drug during Period 2.</time_frame>
      <desc>This is a crossover-design study; a single participant may be represented in up to two different reporting groups.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants receiving Placebo doses three times daily</description>
        </group>
        <group group_id="E2">
          <title>MK-0941 5mg</title>
          <description>Participants receiving MK-0941 5 mg doses three times daily</description>
        </group>
        <group group_id="E3">
          <title>MK-0941 10mg</title>
          <description>Participants receiving MK-0941 10 mg doses three times daily</description>
        </group>
        <group group_id="E4">
          <title>MK-0941 20mg</title>
          <description>Participants receiving MK-0941 20 mg doses three times daily</description>
        </group>
        <group group_id="E5">
          <title>MK-0941 40mg</title>
          <description>Participants receiving MK-0941 40 mg doses three times daily. One participant randomized to receive MK-0941 10 mg during Period 1 and MK-0941 40 mg during Period 2 received MK-0941 10 mg during both Periods 1 and 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

